Cost-effectiveness of atypical antipsychotic medications versus conventional medication

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 13, 2006, Pages 1749-1758

  Hanrahan, Patricia ^a   Luchins, Daniel J ^a   Fabian, Robert ^b   Tolley, George ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b RCF Inc   (United States)

Author keywords

Atypical antipsychotic medication; Cost effectiveness; Mental illness; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; PATHOLOGY; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 37849042640     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.13.1749     Document Type: Review

References (40)

1. KESSLER RC, BIRNBAUM H, DEMLER O et al.: The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol. Psychiatry (2005) 58(8):668-676. (Pubitemid 41565582)
2. WU EQ, BIRNBAUM HG, SHI L et al.: The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry (2005) 66(9):1122-1129. • Recent and fairly inclusive estimate of the costs of schizophrenia. (Pubitemid 41442278)
3. PALMER BA, PANKRATZ VS, BOSTWICK JM: The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry. (2005) 62(3):247-253. (Pubitemid 40990969)
4. SUSSER E, LIN SP, CONOVER S: Risk factors for homelessness among patients admitted to a state hospital. Am. J. Psychiatry (1991) 148:1659-1664.
5. THORNICROFT G, TANSELLA M, BECKER T et al.: The personal impact of schizophrenia in Europe. Schizophr. Res. (2004) 69(2-3):125-132. (Pubitemid 38721411)
6. WYATT RJ, HENTER I, LEARY MC, TAYLOR E: An economic evaluation of schizophrenia - 1991. Social Psychiatry & Psychiatric Epidemiology (1995) 30(5):196-205.
7. GARDNER DM, BALDESSARINI RJ, WARAICH P: Modern antipsychotic drugs: a critical overview. CMAJ Can. Med. Assoc. J. (2005) 172(13):1703-1711. (Pubitemid 40896865)
8. JANICAK PG, DAVIS JM, PRESKORN SH, AYD FJ: Principles and Practice of Psychopharmacotherapy. Williams and Wilkins, Baltimore, MD. (1993):93-177.
9. CAMPBELL M, YOUNG PI, BATEMAN DN, SMITH JM, THOMAS SH: The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. (1999) 47(1):13-22. (Pubitemid 29043159)
10. SCHOOLER NR: Relapse and rehospitalization: comparing oral and depot antipsychotics. J. Clin. Psychiatry (2003) 64(Suppl. 16):14-17. (Pubitemid 37523323)
11. ALMOND S, KNAPP M, FRANCOIS C, TOUMI M, BRUGHA T: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br. J. Psychiatry (2004) 184:346-1345 (Pubitemid 38491171)
12. TORREY WC, DRAKE RE, DIXON L et al.: Implementing evidence-based practices for persons with severe mental illnesses. Psychiatr. Serv. (2001) 52(1):45-50. •• This article provides an excellent overview of the development of several heavily researched psychosocial interventions with demonstrated effectiveness on a range of important outcomes, such as decreased hospitalisations and substance abuse, and increased employment.
13. LIBERMAN RP, KOPELOWICZ A: Recovery from schizophrenia: a concept in search of research. Psychiatr. Serv. (2005) 56(6):735-742. •• This article provides a comprehensive and thought-provoking review of emerging knowledge on the course of recovery from schizophrenia as well as an example of operational definitions of what constitutes recovery.
14. MARSHALL M, LOCKWOOD A: Assertive community treatment for people with severe mental disorders. Cochrane Database Syst. Rev. (2006) 1:CD001089. • Very inclusive substantive and methodological review of Assertive Community Treatment.
15. BOND GR, BECKER DR, DRAKE RE et al.: Implementing supported employment as an evidence-based practice. Psychiatr. Serv. (2001) 52(3):313-322. • Excellent review of research establishing the effectiveness of supported employment.
16. DIXON L, MCFARLANE WR, LEFLEY H et al.: Evidence-based practices for services to families of people with psychiatric disabilities. Psychiatr. Serv. (2001) 52(7):903-910. • Provides a very good overview of the multitude of studies establishing the effectiveness of family psychoeducation.
17. MUESER KT, CORRIGAN PW, HILTON DW et al.: Illness management and recovery: a review of the research. Psychiatr. Serv. (2002) 53(10):1272-1284. • Extensive overview of related research on various psychosocial approaches to managing serious mental illness, raises important substantive issues.
18. DRAKE RE, ESSOCK SM, SHANER A et al.: Implementing dual diagnosis services for clients with severe mental illness. Psychiatr. Serv. (2001) 52(4):469-476. • Excellent overview of emerging evidence supporting Integrated Dual Diagnosis Treatment. For persons with serious mental illnesses and substance abuse problems.
19. LEHMAN AF, STEINWACHS DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr. Bull. (1998) 24:11-20. (Pubitemid 28128487)
20. ANDERSON J, ADAMS C: Family interventions in schizophrenia: an effective but underused treatment. Br. Med. J. (1996) 313:505-506.
21. KANE J, HONINGFELD G, SINGER J, MELTZER H: Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry (1989) 45:789-796.
22. ESSOCK SM, HARGREAVES WA, COVELL NH et al.: Clozapine's effectiveness for patients in state hospitals: results from a randomized study. Psychopharm Bull. (1996) 32:683-697. (Pubitemid 26428274)
23. DAVIS JM, CHEN N, GLICK ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry (2003) 60:553-564. •• This extensive review article provides an important overview of substantive and methodological issues, as well as the efficacy of atypical antipsychotic medications.
24. LEUCHT S, WAHLBECK K, HAMANN J, KISSLING W: New generation antipsychotics versus low potency conventional antipsychotics: a systematic review and meta-analysis. Lancet (2003) 361:1581-1589. (Pubitemid 36578993)
25. MILLER AL, HALL CS, BUCHANAN RWM et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J. Clin. Psychiatry (2004) 65(4):500-508.
26. LITTRELL RA: NASMHPD Medical Directors Best Practice Symposium. October 2000, Philadelphia, PA.
27. HARGREAVES WA, SHUMWAY M, HU TW et al.: Cost Outcome Methods for Mental Health. San Diego, Academic Press (1998). • This book provides an extensive overview of economic analysis as applied to mental health treatment.
28. CHOUINARD G, ALBRIGHT PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J. Clin. Psychopharmacol. (1997) 17(4):298-307. (Pubitemid 27312429)
29. TOLLEY G, KENKEL D, FABIAN R: Valuing Health for policy: An Economic Approach. Chicago: University of Chicago Press (1994). •• This book offers an excellent presentation of economic analysis for providing information relevant to policy decisions.
30. LUCHINS DJ, CHIRIAC I, HANRAHAN P et al.: Allocating funds for medications and psychosocial interventions: How consumers would divide the pie. Psychiatr. Serv. (2005) 56:799-801. •• This exploratory analysis is one of the few applications of contingent valuation with persons having serious mental illness. (Pubitemid 40967455)
31. HAMILTON SH, REVICKI DA, EDGELL ET, GENDUSO LA, TOLLEFSON G: Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics (1999) 15(5):469-480. • Good example of the strengths and limitations of an efficacy study design versus the intent to treat design.
32. TUNIS SL, JOHNSTONE BM, GIBSON PJ, LOOSBROCK DL, DULISSE BK: Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J. Clin. Psychiatry (1999) 60(Suppl. 19):38-45; discussion 46. (Pubitemid 29446952)
33. JERRELL JM: Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr. Bull. (2002) 28(4):589-605. •• This study is noteworthy for its many design strengths including use of the intent to treat approach to analysing outcomes.
34. ROSENHECK R, PERLICK D, BINGHAM S: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA (2003) 290(20):2693-2702. •• From the perspective of effectiveness research, the strengths of this excellent study include broader inclusion criteria in that persons with mental illness and substance use problems participated, and a broader economic analysis that provided information about societal costs, as well as costs from the perspective of the payer. (Pubitemid 37475597)
35. MAHMOUD R: RIS-USA-56C Post Study Investigators' Meeting. Rancho Mirage, California (23-25 January 1998).
36. MAHMOUD R, ENGELHART LM, JANAGAP DD, OSTER G, OLLENDORF D: Risperidone versus conventional antipsyhcotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. Clin. Drug 0Investig. (2004) 24(5):275-286. (Pubitemid 38680228)
37. TOLLEFSON GD, BEASLEY CM, TRAN PV et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry (1997) 154(4):457-465. (Pubitemid 27147597)
38. DUGGAN L, FENTON M, RATHBONE J, DARDENNES R, EL-DOSOKY A, INDRAN S: Olanzapine for schizophrenia. Cochrane Database Syst. Rev. (2006) 1:CD001359.
39. LAMB HR, WEINBERGER LE: The shift of psychiatric inpatient care from hospitals to jails and prisons. J. Am. Acad. Psychiatry Law (2005) 33:529-534. (Pubitemid 43011189)
40. WEISBROD BA. Benefit-cost analysis of a controlled experiment: treating the mentally ill. Journal of Human Resources (1981) 16(4):523-548.